ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug. The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug. The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily. As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear." The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/24/201417:35:36ADR Shares End Mixed; Unilever, AstraZeneca Shares Active
04/24/201415:35:42U.S. Stocks Rise, Buoyed by Apple Results
04/24/201415:20:17Lilly Says Takeda May Not Cover Its Share of $9 Billion Lawsuit
04/24/201412:39:32Novartis Leads Zurich Stocks Lower
04/24/201412:37:47EUROPE MARKETS: European Stocks End Choppy Day In Black
04/24/201410:39:52EUROPE MARKETS: European Stocks Pare Gains On Ukraine Tensions
04/24/201408:00:28Zimmer to Buy Biomet for $13.35 Billion -- Update
04/24/201406:18:32EUROPE MARKETS: European Stocks Strong After Ifo, Draghi Comments
04/24/201404:30:12Novartis 1Q Profit Rises About 23%
04/24/201402:40:06Novartis 1st Quarter Profit Rises About 23%
04/24/201402:27:06Novartis First-Quarter Profit Rises About 23% -- Update
04/22/201413:06:07LONDON MARKETS: Glaxo, AstraZeneca Lead U.K. Stocks To Two-week...
04/22/201412:38:25EUROPE MARKETS: Drug Stocks Drive European Markets Higher
04/22/201412:35:06Novartis 1Q 2014 -- Forecast
04/22/201409:50:05Glaxo Exits Cancer Drugs
04/22/201409:44:35LONDON MARKETS: Glaxo, AstraZeneca Lead Gains In U.K. Stocks
04/22/201409:34:59U.S. Stock Futures Trade Flat
04/22/201408:32:05Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201405:51:23Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201404:40:14European Stocks Start Strongly After Easter Holiday

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad